You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

2

3

▼  4th Inning 0 outs

Blueprint Medicines to collaborate on cancer drugs with Wellcome Trust Sanger Institute, MGH

Blueprint Medicines, a Cambridge company that seeks to harness the potential of cancer genomics, said Tuesday that it is looking to advance its research into potential cancer treatments by collaborating with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center.

Launched in 2011 by Third Rock Ventures, a Boston-based venture capital firm focused on the life sciences industry, Blueprint is looking to develop personalized, highly-selective cancer therapies.

Continue reading below

To that end, Blueprint has assembled a library of compounds that may have the potential to become personalized cancer therapies focused on specific genetic abnormalities.

Under the collaborations, Sanger and MGH will utilize this library and screen Blueprint’s compounds against panels of cancer cell lines and evaluate their activity toward particular cancer targets.

This effort could potentially identify new cancer targets for Blueprint’s future drug candidates to focus on.

In a statement, Chris Varma, president and chief executive of Blueprint Medicines, said: “Our discovery process begins with a genomic blueprint of specific patient populations and the utilization of our proprietary genomics platform which rapidly identifies novel targets and potential combination partners. We have now built a pioneering chemical library of novel compounds that covers the majority of the kinome, some of which to be used in this collaboration, with selectivity that far surpasses prior generations of kinase inhibitors.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.